LeMaitre Vascular

LMAT

Market cap $2.16B

CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid sales/EPS growth estimates and big one-year gains.

LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.

CGI reported a good quarter with revenue up 3.3% to $4.16B and diluted EPS up 10.6% to $2.09. Revenue growth was driven by acquisitions. ADP reported a strong quarter with revenue up 7% and adjusted EPS up 12%. Employer Services grew 7% to $3.3B on strong client retention and new business bookings. Since I started this portfolio in September 2017, I have received a total of $36,112.67 CAD in dividends.

BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.

LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT.

LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.

LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript

LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.48 per share a year ago.